Johnson And Johnson's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Johnson And Johnson in the second quarter 2026?
Johnson and Johnson achieved a return on average equity (ROE) of 25.74 % in its second quarter 2026, this is above JNJ's average return on equity of 24.23%.
Johnson And Johnsons equity during the 12 months ending in the second quarter 2026 are valued at $81 billion

ROE fell compared to the first quarter 2026, despite the net income growth of 5.71% from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 29 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 485 to 486.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 28 2026) II. Quarter	(Mar 29 2026) I. Quarter	(Dec 28 2025) IV. Quarter	(Sep 28 2025) III. Quarter	(Jun 29 2025) II. Quarter
Y / Y Equity Change	8.28 %	3.94 %	14.06 %	13 %	-
Y / Y Net Income Change	-0.05 %	-52.4 %	49.11 %	91.24 %	18.16 %
Net Income (TTM) in Millions	21,037	21,040	26,804	25,119	22,661
Return On Equity (TTM)	25.74 %	26.26 %	33.78 %	32.69 %	30.39 %
JNJ's Total Ranking	# 486	# 485	# 272	# 295	# 304
Equity (TTM) in Millions	84,971	81,186	81,544	79,277	78,473
Seq. Equity Change	4.66 %	-0.44 %	2.86 %	1.02 %	0.47 %
Seq. Net Income Change	5.71 %	2.33 %	-0.7 %	-6.95 %	-49.66 %

Back to JNJ Management Effectiveness >> JNJ's 5 Years Annual ROE >> Compare JNJ ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 30
Sector	# 64
Overall	# 486

Return On Equity Statistics
High	Average	Low
54.01 %	24.23 %	1.85 %
(Jun 30 2024)

JNJ Annual Return On Equity	(Dec 28 2025) 2025	(Dec 29 2024) 2024	(Dec 31 2023) 2023	(Jan 01 2023) 2022	(Jan 02 2022) 2021
Total Equity in Millions	81,544	71,490	68,774	76,804	74,023
Y / Y Equity Change	14.06 %	3.95 %	-10.46 %	3.76 %	16.98 %
Net Income in Millions	26,804	14,066	35,153	17,941	20,878
Y / Y Net Income Change	90.56 %	-59.99 %	95.94 %	-14.07 %	41.89 %
Return On Equity	32.87 %	19.68 %	51.11 %	23.36 %	28.2 %

Back to JNJ Management Effectiveness >> JNJ's 5 Years Annual ROE >> Compare JNJ ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 32.87 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
JNJ's' Return on Equity at Yahoo Finance
JNJ's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for JNJ's Competitors
Subscribers only: Roe for Johnson And Johnson's Suppliers
Subscribers only: Return On Equity for JNJ's Customers

Companies with similar Return On Equity at Jun 28 2026, within Healthcare Sector	ROE
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %

Date modified: 2026-09-26T07:18:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.